Cost-effectiveness of sacituzumab govitecan in hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer

Cost-effectiveness of sacituzumab govitecan in hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer

BackgroundThe efficiency and safety of sacituzumab govitecan (SG) for the therapy of hormone receptor-positive (HR+)/human epidermal receptor 2-negative (HER2-) metastatic breast cancer (BC) has been demonstrated. The aim of this study is to evaluate its cost-effectiveness on HR+/HER2- metastatic BC...

Full description

Bibliographic Details
Main Authors: Demin Shi, Yan Li, Xueyan Liang, Lingyuan Chen
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-05-01
Series:Frontiers in Oncology
Subjects:
cost-effectiveness
sacituzumab govitecan
breast cancer
hormone receptor-positive
human epidermal receptor 2-negative
partitioned survival model
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1162360/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1162360/full

Similar Items